These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 19047631)

  • 1. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment.
    Colussi C; Mozzetta C; Gurtner A; Illi B; Rosati J; Straino S; Ragone G; Pescatori M; Zaccagnini G; Antonini A; Minetti G; Martelli F; Piaggio G; Gallinari P; Steinkuhler C; Clementi E; Dell'Aversana C; Altucci L; Mai A; Capogrossi MC; Puri PL; Gaetano C
    Proc Natl Acad Sci U S A; 2008 Dec; 105(49):19183-7. PubMed ID: 19047631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoplasmic HDAC4 regulates the membrane repair mechanism in Duchenne muscular dystrophy.
    Renzini A; Marroncelli N; Cavioli G; Di Francescantonio S; Forcina L; Lambridis A; Di Giorgio E; Valente S; Mai A; Brancolini C; Giampietri C; Magenta A; De Santa F; Adamo S; Coletti D; Moresi V
    J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1339-1359. PubMed ID: 35170869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat.
    Consalvi S; Mozzetta C; Bettica P; Germani M; Fiorentini F; Del Bene F; Rocchetti M; Leoni F; Monzani V; Mascagni P; Puri PL; Saccone V
    Mol Med; 2013 May; 19(1):79-87. PubMed ID: 23552722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arginine butyrate: a therapeutic candidate for Duchenne muscular dystrophy.
    Vianello S; Yu H; Voisin V; Haddad H; He X; Foutz AS; Sebrié C; Gillet B; Roulot M; Fougerousse F; Perronnet C; Vaillend C; Matecki S; Escolar D; Bossi L; Israël M; de la Porte S
    FASEB J; 2013 Jun; 27(6):2256-69. PubMed ID: 23430975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors.
    Minetti GC; Colussi C; Adami R; Serra C; Mozzetta C; Parente V; Fortuni S; Straino S; Sampaolesi M; Di Padova M; Illi B; Gallinari P; Steinkühler C; Capogrossi MC; Sartorelli V; Bottinelli R; Gaetano C; Puri PL
    Nat Med; 2006 Oct; 12(10):1147-50. PubMed ID: 16980968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-146a deficiency does not aggravate muscular dystrophy in mdx mice.
    Bronisz-Budzyńska I; Chwalenia K; Mucha O; Podkalicka P; Karolina-Bukowska-Strakova ; Józkowicz A; Łoboda A; Kozakowska M; Dulak J
    Skelet Muscle; 2019 Aug; 9(1):22. PubMed ID: 31412923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and localization of protein inhibitor of neuronal nitric oxide synthase in Duchenne muscular dystrophy.
    Guo Y; Petrof BJ; Hussain SN
    Muscle Nerve; 2001 Nov; 24(11):1468-75. PubMed ID: 11745948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heme Oxygenase-1 Influences Satellite Cells and Progression of Duchenne Muscular Dystrophy in Mice.
    Pietraszek-Gremplewicz K; Kozakowska M; Bronisz-Budzynska I; Ciesla M; Mucha O; Podkalicka P; Madej M; Glowniak U; Szade K; Stepniewski J; Jez M; Andrysiak K; Bukowska-Strakova K; Kaminska A; Kostera-Pruszczyk A; Jozkowicz A; Loboda A; Dulak J
    Antioxid Redox Signal; 2018 Jul; 29(2):128-148. PubMed ID: 29669436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanism of sphingosine-1-phosphate action in Duchenne muscular dystrophy.
    Nguyen-Tran DH; Hait NC; Sperber H; Qi J; Fischer K; Ieronimakis N; Pantoja M; Hays A; Allegood J; Reyes M; Spiegel S; Ruohola-Baker H
    Dis Model Mech; 2014 Jan; 7(1):41-54. PubMed ID: 24077965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proof-of-concept validation of the mechanism of action of Src tyrosine kinase inhibitors in dystrophic mdx mouse muscle: in vivo and in vitro studies.
    Sanarica F; Mantuano P; Conte E; Cozzoli A; Capogrosso RF; Giustino A; Cutrignelli A; Cappellari O; Rolland JF; De Bellis M; Denora N; Camerino GM; De Luca A
    Pharmacol Res; 2019 Jul; 145():104260. PubMed ID: 31059789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenic impairment of the vascular endothelium: a novel mechanism and potential therapeutic target in muscular dystrophy.
    Palladino M; Gatto I; Neri V; Straino S; Smith RC; Silver M; Gaetani E; Marcantoni M; Giarretta I; Stigliano E; Capogrossi M; Hlatky L; Landolfi R; Pola R
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2867-76. PubMed ID: 24072696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway.
    Cacchiarelli D; Martone J; Girardi E; Cesana M; Incitti T; Morlando M; Nicoletti C; Santini T; Sthandier O; Barberi L; Auricchio A; Musarò A; Bozzoni I
    Cell Metab; 2010 Oct; 12(4):341-351. PubMed ID: 20727829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
    Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
    FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients.
    Mozzetta C; Sartorelli V; Steinkuhler C; Puri PL
    Trends Mol Med; 2024 Mar; 30(3):278-294. PubMed ID: 38408879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transgenic overexpression of ADAM12 suppresses muscle regeneration and aggravates dystrophy in aged mdx mice.
    Jørgensen LH; Jensen CH; Wewer UM; Schrøder HD
    Am J Pathol; 2007 Nov; 171(5):1599-607. PubMed ID: 17982130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutraceutical and pharmaceutical cocktails did not improve muscle function or reduce histological damage in D2-mdx mice.
    Spaulding HR; Quindry T; Hammer K; Quindry JC; Selsby JT
    J Appl Physiol (1985); 2019 Oct; 127(4):1058-1066. PubMed ID: 31295065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal by relaxin of altered ileal spontaneous contractions in dystrophic (mdx) mice through a nitric oxide-mediated mechanism.
    Baccari MC; Nistri S; Vannucchi MG; Calamai F; Bani D
    Am J Physiol Regul Integr Comp Physiol; 2007 Aug; 293(2):R662-8. PubMed ID: 17522128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlated NOS-Imu and myf5 expression by satellite cells in mdx mouse muscle regeneration during NOS manipulation and deflazacort treatment.
    Anderson JE; Vargas C
    Neuromuscul Disord; 2003 Jun; 13(5):388-96. PubMed ID: 12798794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological control of cellular calcium handling in dystrophic skeletal muscle.
    Ruegg UT; Nicolas-Métral V; Challet C; Bernard-Hélary K; Dorchies OM; Wagner S; Buetler TM
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S155-61. PubMed ID: 12206810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.